Recording: Identification and management of patients with nmCRPC
The treatment landscape of advanced prostate cancer has evolved dramatically in the past decade, with the ultimate approval of several novel life-prolonging agents. Androgen-deprivation therapy for treating primary localized/locally advanced tumor or biochemical recurrence after local therapies invariably leads to a castration-resistant state, which, however, can occur before the actual detection of metastases on conventional imaging.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | Not approved |
| Duration | Approx. 80 minutes |
This particular disease entity is known as non-metastatic castration-resistant prostate cancer (nmCRPC). Within this disease state, a subgroup of patients is at a particularly high risk of developing metastatic disease progression. This so-called high-risk nmCRPC subgroup is characterized by a PSA DT ≤10 months at a PSA of >2 ng/ml.
This webinar is focused on the latest advances in the management of high-risk nmCRPC, including mature data from pivotal randomized clinical trials testing the novel anti-androgens apalutamide, darolutamide and enzalutamide, which are now recommended as the standard of care in this space. An interactive discussion with clinical cases will address the most common diagnostic and therapeutic challenges in this setting, with attention to the role of novel functional imaging techniques.